dwinnex.com

Amicus Therapeutics, Inc. [NASDAQ:FOLD]: Analyst Rating and Earnings

Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Amicus Therapeutics, Inc. [FOLD] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give FOLD an Outperform rating. Its stock price has been found in the range of 8.27 to 17.62. This is compared to its latest closing price of $12.87.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Amicus Therapeutics, Inc. [FOLD] is sitting at 1.64. This is compared to 1 month ago, when its average rating was 1.70.

For the quarter ending in Dec-18 Amicus Therapeutics, Inc. [FOLD] generated $0.03 billion in sales. That’s 8.06% higher than the average estimate of $0.03 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Tue 14 May (In 25 Days).

Fundamental Analysis of Amicus Therapeutics, Inc. [FOLD]

Now let’s turn to look at profitability: with a current Operating Margin for Amicus Therapeutics, Inc. [FOLD] sitting at -356.71 and its Gross Margin at +79.59.

This company’s Return on Total Capital is -55.07, and its Return on Invested Capital has reached -49.50%. Its Return on Equity is -100.32, and its Return on Assets is -49.26. These metrics suggest that this Amicus Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Amicus Therapeutics, Inc. [FOLD] has generated a Total Debt to Total Equity ratio of 93.83. Similarly, its Total Debt to Total Capital is 48.41, while its Total Debt to Total Assets stands at 40.73. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 93.83, and its Long-Term Debt to Total Capital is 48.41. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -9.47. The Enterprise Value to Sales for this firm is now 33.35, and its Total Debt to Enterprise Value stands at 0.20. Amicus Therapeutics, Inc. [FOLD] has a Price to Book Ratio of 5.29.

Shifting the focus to workforce efficiency, Amicus Therapeutics, Inc. [FOLD] earns $179,616 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.81 and its Total Asset Turnover is 0.13. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 6.30 and its Current Ratio is 6.40. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Amicus Therapeutics, Inc. [FOLD] has 216.39M shares outstanding, amounting to a total market cap of $2.75B. Its stock price has been found in the range of 8.27 to 17.62. At its current price, it has moved by -27.98% from its 52-week high, and it has moved 53.45% from its 52-week low.

This stock’s Beta value is currently 1.84, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 41.87. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Amicus Therapeutics, Inc. [FOLD] a Reliable Buy?

Amicus Therapeutics, Inc. [FOLD] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.